Loading
A phase 1/2 trial of Oleclumab and Osimertinib in non-small-cell lung cancer, run by MedImmune LLC, active and no longer recruiting.
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study is a phase 1/2 interventional study registered as NCT03381274 by MedImmune LLC, with 43 participants enrolled, started 2018-05-08 and due to reach its primary completion in 2021-05-24. Interventions recorded: Oleclumab, Osimertinib and AZD4635. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
43 enrolled.
95% CI 5.4 to 41.9; Figures from the ClinicalTrials.gov results section (first posted 2022-07-26), not from a publication
Source95% CI 1.4 to NA; Figures from the ClinicalTrials.gov results section (first posted 2022-07-26), not from a publication · 95% CI 12.3 to NA · 95% CI 1.0 to 16.4 · 95% CI 1.5 to NA · 95% CI 1.9 to NA
Source95% CI 1.4 to 19.8; Figures from the ClinicalTrials.gov results section (first posted 2022-07-26), not from a publication · 95% CI 3.7 to NA · 95% CI 0.5 to 1.8 · 95% CI 0.8 to 5.5 · 95% CI 1.4 to 2.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2primary | Oleclumab Dose 2 + Osimertinib Dose 1 | 21 | 19% | - | - | link |
| Overall Survival (OS) for Parts 1 and 2 | Oleclumab Dose 1 + Osimertinib Dose 1 | 5 | 21.9 months | - | - | link |
| Oleclumab Dose 2 + Osimertinib Dose 1 | 21 | 24.8 months | ||||
| Oleclumab Dose 1 + AZD4635 Dose 1 | 6 | 16.4 months | ||||
| Oleclumab Dose 1 + AZD4635 Dose 2 | 6 | 27.4 months | ||||
| Oleclumab Dose 2 + AZD4635 Dose 2 | 5 | 7.1 months | ||||
| Progression Free Survival (PFS) for Parts 1 and 2 | Oleclumab Dose 1 + Osimertinib Dose 1 | 5 | 6.5 months | - | - | link |
| Oleclumab Dose 2 + Osimertinib Dose 1 | 21 | 11 months | ||||
| Oleclumab Dose 1 + AZD4635 Dose 1 | 6 | 1.4 months | ||||
| Oleclumab Dose 1 + AZD4635 Dose 2 | 6 | 1.8 months | ||||
| Oleclumab Dose 2 + AZD4635 Dose 2 | 5 | 1.9 months |
Shares Osimertinib, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.